Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propel vs Triamcinolone-soaked Nasopore in Chronic Rhinosinusitis
NCT03729310Phase 1Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2020
- Primary completion
- May 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of triamcinolone acetonide in chronic rhinosinusitis (CRS), sponsored by Weill Cornell Medicine. Primary endpoint: Perioperative Sinus Endoscopy at 12 weeks. Planned start Mar 2020; status: withdrawn.
02
Drugs
triamcinolone acetonide
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT03729310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729310.